Ashley, a renowned researcher, entrepreneur and clinician, brings extensive leadership experience across healthcare research institutions and private organizations. He currently serves as chair of the Dept. of Medicine at Stanford Health.
Research areas for Ashley span precision medicine, data science, AI and digital health. His track record includes co-founding seven biotechnology companies in the past. He also serves as co-director for Stanford’s biomedical innovation-translation program, Catalyst. The Catalyst program invests in the university’s most promising biomedical innovations.
Dexcom, a leader in continuous glucose monitoring (CGM) and one of the largest diabetes tech companies in the world, says he brings its board a clinical perspective for strategic guidance related to medtech development and healthcare innovation.
Read more about Dexcom and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
“We are thrilled to announce Euan’s appointment to the Dexcom Board today,” said Jake Leach, president and interim CEO at Dexcom. “Dexcom is well-positioned to advance metabolic health and improve quality of life for millions of people globally. Euan’s leadership across the intersections of clinical practice and key advances in healthcare innovation will strengthen us as we continue to advance our biosensing technology across the spectrum of metabolic health.”
Dr. Eric Topol, director of the Scripps Translational Science Institute, said he recently completed his board service at Dexcom. He says Ashley sat “at the top of my list” when collaborating with management on clinical leaders to consider for the board.
“He will provide an excellent perspective for Dexcom as they build on their incredible growth journey,” Topol said.
Ashley’s experience includes nearly two decades spent at Stanford University, including charing the Dept. of Medicine since 2024. His co-founded biotech companies include Personalis, Deepcell, Svexa, Saturnus and Swift Bio. He also joined AstraZeneca’s board in 2020 and remains a director at the pharmaceutical giant.
